BioStock interviews Martin Linhult, CombiGene’s new CMC expert

Jan 12, 2021

BioStock has spoken with the newly recruited CMC expert Martin Linhult who, with his long experience of bringing pharmaceuticals to the market, will primarily focus on the manufacturing process of CG01, which is developed for the treatment of drug resistant
focal epilepsy.

Read the full interview with Martin Linhult at biostock.se:
https://www.biostock.se/en/interview-with-combigenes-new-cmc-expert/

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Agavägen 52A, SE-181 55 Lidingö

 

Linked In     Twitter      Facebook